Search results
Results from the WOW.Com Content Network
The Generalized Anxiety Disorder 7-item scale (GAD-7) is a widely used self-administered diagnostic tool designed to screen for and assess the severity of generalized anxiety disorder (GAD). [1] Comprising seven items, the GAD-7 measures the frequency of anxiety symptoms over the past two weeks, with respondents rating each item on a scale from ...
The GAD-7 showed good sensitivity to treatment effects in two randomized-controlled trials. [35] Clinical utility Excellent The GAD-7 is brief, free to use, and easy to score. [19] It is sensitive to change following treatment. [35] There is some evidence that elderly people may require some help to complete the scale accurately. [33] PHQ-15
The GAD-7 is a seven-item anxiety screening instrument developed in 2006 with a similar format to that of the PHQ-9. [20] Total scores range from 0 to 21 with scores of 5, 10, and 15 indicating mild, moderate, and severe anxiety. Unlike the PHQ-9, clinicians use the GAD-7 to assess the severity of anxiety only.
Using a cut-off of 8 the GAD-7 has a sensitivity of 92% and specificity of 76% for diagnosis generalized anxiety disorder. The following cut-offs correlate with level of anxiety severity: Score 0-4: Minimal Anxiety; Score 5-9: Mild Anxiety; Score 10-14: Moderate Anxiety; Score greater than 15: Severe Anxiety
The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S.
Generalized Anxiety Disorder 7 (GAD-7) [4] [5] Hamilton Anxiety Scale (HAM-A) [6] [7] Hospital Anxiety and Depression Scale; Panic and Agoraphobia Scale (PAS) Panic Disorder Severity Scale (PDSS) PTSD Symptom Scale – Self-Report Version; Screen for child anxiety related disorders; Social Phobia and Anxiety Inventory-Brief form; Social Phobia ...
Pharmaceutical giant Pfizer (NYSE: PFE) stands out in this context. The company currently offers a mouthwatering 5.7% dividend yield -- the highest among major drug manufacturers and one of the ...
Pfizer-BioNTech has begun testing a third dose of its COVID-19 vaccine in a small group of people. The vaccine is currently authorized in several countries in a two-dose regimen, given 21 days ...